论文部分内容阅读
应用测定Epstein-Barr病毒(EB病毒)IgA/EA抗体的改进方法(见病毒学报,2:372,1986).将待检血清用与抗人IgG血清或葡萄球菌菌体蛋白(SPA)吸附,除去了竞争性IgG类抗体,增加了血清中IgA抗体与抗原相结合的机率,从而提高了免疫酶法的敏感性和鼻咽癌的检出率。用此法我们检查了来本实验室检查EB病毒相关抗体的2045人,大部份是进行体格检查、无自觉症状的健康人,其查出IgA/EA抗体阳性者42人,进一步做病理检查证实27人患鼻咽癌,其中属临床Ⅰ期者10人,Ⅱ期10人,Ⅲ期6人,
Application of an improved method for the determination of Epstein-Barr virus (EBV) IgA/EA antibody (see Journal of Virology, 2:372, 1986). The serum to be tested is adsorbed with anti-human IgG serum or Staphylococcus aureus protein (SPA). Removal of competitive IgG antibodies increased the probability of combining serum IgA antibodies with antigens, thereby increasing the sensitivity of the immunoenzymatic assay and the detection rate of nasopharyngeal carcinoma. Using this method, we examined 2,045 people who came to our laboratory to examine EB virus-related antibodies. Most of them were healthy people who had undergone a physical examination and had no symptoms. They detected 42 positive IgA/EA antibodies and performed further pathological examinations. It was confirmed that 27 people had nasopharyngeal carcinoma, of whom 10 were clinical stage I, 10 were stage II, and 6 were stage III.